





Understanding the structural differences among M1-class 
aminopeptidases and development of novel inhibitors 
Introduction 
Proteins or enzymes are important biological machinery essential for the normal and 
healthy growth of every living cell. In vivo, every protein or enzyme has its specific 
function. Once the biological role of a particular enzyme is fulfilled, it undergoes 
proteolytic degradation and forms individual amino acids. These free amino acids are 
again recycled into a functional protein whenever required. In nature, different 
kingdoms of life have their own proteolytic machinery for protein degradation. But 
unique machinery is present among all kingdoms of life in the form of endopeptidases 
and exopeptidases which are essential in the final stages of the protein degradation 
pathway. 
 Aminopeptidases catalyze the hydrolysis of amino acids from the amino 
terminus of the small peptides. M1 family aminopeptidases play important role in the 
pathogenicity of bacteria and shown to be critical in many physiological processes such 
as regulation of peptide hormone levels, protein maturation, cell cycle regulation, 
memory, antigen presentation, and angiogenesis in humans. They are mono zinc-
containing enzymes which are involved in the release of free amino acids from smaller 
peptides. Except for viruses these enzymes are present in all kingdoms of life. To date, 
there are twelve members of the M1 class represent in humans. Some of them are 
membrane-bound and others are found in the cytosol. Most of the M1 class 
aminopeptidases are reported to be drug targets in various diseases in addition to having 
aminopeptidase activity. Due to the essential roles played by these enzymes, much 
emphasis was given to their biochemical and structural characterization. In addition, 
M1 class proteases from the archaea and bacterial origin are also structurally 
characterized. These are F3 from Thermoplasma acidophilum, aminopeptidase N from 
Neisseria Meningitides (NmAPN), aminopeptidase N from Plasmodium falciparum 
(PfA-M1), and aminopeptidase N from Escherichia coli (ePepN). 
All the M1 class proteases exist as multi-domain proteins. Domains arrangement 
around the catalytic domain, zinc-binding motif (HEXXH motif), and exopeptidase 





this family have the same catalytic principles. They all have unique amino terminus 
recognition pattern where the carboxy terminus of three glutamates co-ordinates with 
the zinc. Specificity was derived due to the natural variation in residues around the 
substrate-binding pocket or S1 pocket. All the M1 class proteases consist of an 
archetypical S1 pocket including ePepN. In the present study, ePepN has been used as 
a prototype in understanding the biochemical properties and structural basis of M1-
class aminopeptidases. In this protein, the exopeptidase motif (GXMEN motif) was 
preceded by methionine (M260) which acts as a gatekeeper in the S1 pocket and 
accommodates the peptides with a diverse range of residues at the P1 position. 
 The work executed in this thesis entitled “Understanding the structural 
differences among M1-class aminopeptidases and development of novel inhibitors” 
was undertaken with an aim of understanding the role of specific residues on the activity, 
stability, substrate specificity, and protein-ligand interactions of M1 class proteases. In 
this study, we worked on two proteases from this family namely, aminopeptidase A 
from Legionella pneumophila (LePepA) and aminopeptidase N from Plasmodium 
falciparum (PfA-M1). We carried out site-directed mutagenesis on specific residues of 
LePepA and different mutants were generated (LePepA-K132E, LePepA-K132L, and 
LePepA-S276M). Their biochemical properties, kinetic parameters were determined 
and the structural basis was provided for the unique substrate specificity of LePepA. In 
this study, we also have designed a library of hydroxamic acid-based leucine ureido 
derivatives to discover molecules that can specifically inhibit PfA-M1 with a novel 
mode of binding. By analyzing the structural data obtained from different PfA-M1-
inhibitor complexes, we synthesized an inhibitor molecule that has a high degree of 
selectivity towards PfA-M1 over its mammalian counterpart porcine aminopeptidase N 
(PmAPN).  
 This thesis has been divided into four chapters. Chapter 1 discusses the 
introduction, conservation pattern, biochemical, structural information, and 
pathophysiological roles of different M1 class proteases from humans. It provides the 
information about the S1 pocket of M1 class aminopeptidases. Chapter 2 describes the 
materials and methods employed to execute this work. Chapter 3 and chapter 4, each 
chapter is subdivided into three sections. Section 1 is an introduction, section 2 results 





biochemical, mechanistic and structural studies of a unique Glu/Asp specific M1 class 
aminopeptidase from Legionella pneumophila”. Chapter 4 deals with “Design and 
synthesis of PfA-M1 selective inhibitors over mammalian counterpart as an 
antimalarial agent and structural evaluation”. 
 
Statement of problem 
Most of the M1 family aminopeptidases studied till date are displayed broad substrate 
specificity, mostly specific to hydrophobic and basic residues. This is explained by the 
presence of hydrophobic S1 pocket in the active site of ePepN along with polar residues 
at the rooftop of the active site. Methionine at gatekeeper position (M260) followed by 
methionine in the exopeptidase motif (GXM263EN) contributes to the hydrophobicity 
of the S1 pocket in ePepN. In the case of human aminopeptidase A (hAPA) with 
additional substrate specificity towards acidic residues, a polar residue (T356) occupied 
the gatekeeper position and diluted the hydrophobicity of the S1 pocket. From this 
observation, we anticipated that if there could be a member from the M1 class 
aminopeptidase that has both the methionine residues, one at gatekeeper position 
(M260) and the other in the exopeptidase motif (M263) are substituted by polar residues, 
and may have higher substrate specificity towards acidic residues. To find out the M1-
class aminopeptidase with two polar residues at both gatekeeper and exopeptidase 
methionine positions, we performed an unbiased search, by providing query sequence 
“X-G-X-X-E-X (2,100)-H-E-X (2)-H-X (18)-E” ( Where X represents variable amino 
acid) which includes signature motifs (exopeptidase motif and zinc-binding motif) of 
M1 class against the PROSITE database using the ScanProsite tool. 100 sequences were 
identified out of ~10,000 hits to have polar residues (Z-G-X-Z-E-X, Where Z represents 
the polar residue) at both the methionine positions. 25 of these 100 sequences consists 
of serine at both gatekeeper (S273) and exopeptidase (GAS276EP) positions. 
Interestingly we found that all these 25 sequences belonged to only Legionella species. 
 In this study, to meet the first objective, we focused on the biochemical and 
structural properties of aminopeptidase A from the extensively studied pathogen 
Legionella pneumophila (LePepA). In this protein, the gatekeeper residue (S273) and 
the residue in the exopeptidase motif (GAS276EP) are polar and the rooftop of the 





hydrophobic residues at gatekeeper position (M260) and exopeptidase motif 
(GAM263EN) and polar but not charged residues at the rooftop of ePepN active site. 
Due to the increased polarity of the wall of the cylinder and positively charged rooftop 
of the S1 pocket, we speculated that LePepA would have different substrate specificity, 
preferably toward acidic residues in contrast to basic and hydrophobic residues in the 
ePepN. LePepA may have evolved to fulfill the specific functions in Legionella species. 
Recently published report on crystal structure of hAPA revealed that a polar residue 
(T356) at the gatekeeper position is involved in stabilization of the substrate with 
glutamate at P1 position by hydrogen bonds and also positively charged residue (R887) 
at the rooftop of the active site forms a salt bridge with the glutamate at P1 position. 
These observations strongly support our reasoning of unique specificity of LePepA 
towards only acidic residues. To confirm our predictions and for further studies we have 
cloned this protein, purified, and crystallized. 
 The second objective of this study is to develop selective inhibitors against 
PfA-M1. Plasmodium parasites causing malaria has developed resistance to most of the 
antimalarials in use, including the artemisinin-based combinations, which are the last 
line of defense against malaria. This necessitates for the discovery of new targets and 
the development of new antimalarials. Aminopeptidase N from Plasmodium falciparum 
(PfA-M1), an M1 class aminopeptidase, is essential for the asexual erythrocytic stage 
of development. This enzyme has been validated as a potential antimalarial drug target. 
Herein we describe the design, synthesis, in vitro and cell based evaluation of a library 
of compounds with leucine hydroxamic acid attached to urea-substituted groups. The 
design is to extend the binding of molecules beyond S2’ pocket of the enzyme to achieve 
the much-needed specificity. Most of the 40 compounds described in this study 
displayed inhibition at sub-micromolar range against the recombinant PfA-M1 with 
negligible cytotoxicity on human cell lines and strong inhibition of the malarial parasite 
growth. However, the selectivity index between the malarial and mammalian M1 
aminopeptidases for all these compounds is very less except for compound 39, which 
has an inclination towards parasite enzyme, by more than 700 fold. Crystal structures 
of PfA-M1 at atomic resolution in complex with at least nine different compounds 
including compound 39 establish the structural basis for the observed inhibition. 





malarial and mammalian enzymes are apparent. Together, our data provide important 
insights for the rational and structure-based design of potent and selective inhibitors of 
PfA-M1 that will likely lead to novel chemotherapeutics for the treatment of malaria. 
 
Objectives 
1. Discovery, biochemical, mechanistic and structural studies of a unique Glu/Asp 
specific M1 class aminopeptidase from Legionella pneumophila. 
2. Design and synthesis of PfA-M1 selective inhibitors over mammalian counterpart as 
an antimalarial agent and structural evaluation. 
 
Methodologies used and sample results: 
Discovery, biochemical, mechanistic and structural studies of a unique Glu/Asp 
specific M1 class aminopeptidase from Legionella pneumophila (LePepA) 
 
Activity and substrate specificity of LePepA: 
The full-length gene of aminopeptidase A from Legionella pneumophila (LePepA) was 
cloned, expressed and purified to homogeneity (900 amino acids protein). Activity 
assays were performed with 15 aminoacyl-pNAs and 4 aminoacyl-AMCs as substrates 
against the purified enzyme. Interestingly LePepA preferred only acidic residues as we 
predicted from our earlier bioinformatics studies. 
 
Figure. Enzymatic activity of LePepA with different substrates. 
The activity of LePepA against the Glu-pNA was set to 100 % and compared relative activities 






Residues in the S1 pocket and rooftop regions are critical for unique specificity toward acidic 
residues:  
 
To provide the structural basis for the biochemical properties of the LePepA, we have 
crystallized the enzyme and solved the crystal structures in the apo form and in complex 
with glutamate and aspartate. The overall structure of the LePepA is folded into four-
domains with thermolysin like catalytic domain. Similar to ePepN structure, LePepA 
adopted the closed conformation. A single zinc ion is observed in the active site of the 
apo structure with conserved H310EFFHX(18)E333 zinc-binding motif. Strong 
electron density was observed for E311 and Y383 which are critical for peptide 
hydrolysis. E311 activates nucleophilic water and Y383 stabilizes oxyanion that results 
from the nucleophilic addition of water on the peptide bond. Representation of S1 
pocket as a cylinder could be reconstructed for the LePepA. Two serine residues present 
in the S273GAS276EP motif are locked by a weak hydrogen bond (3.8 Å). K132 and 
R375 occupied in the rooftop of the S1 pocket and positioned to interact with the 
incoming glutamate or aspartate containing substrates. K132 involved in hydrogen 
bonding with the main chain carbonyl of the E134 (2.6 Å) and S276 (3.1 Å). Similar to 
ePepN, three glutamates (E134, E277, and E333) involved in the formation of an anion 
hole that would accommodate the α-amino group of N-termini of the peptide substrate. 
 
Design and synthesis of PfA-M1 selective inhibitors over mammalian counterpart 
as antimalarial agents and structural evaluation 
 
Library screening against PfA-M1 and PmAPN: 
Fresh stocks of all 40 compounds and control molecule actinonin were made in the 
dimethyl sulfoxide (DMSO) to a stock concentration of 10 mM. IC50 was determined 
against PfA-M1, PmAPN using seven different concentrations of inhibitor in the range 
between 0.016 µM and 100 µM at 200 µM of substrate (Leu-pNA) concentration. IC50 
data was determined using SigmaPlot 13. The Ki value for all compounds against PfA-
M1 was determined by the Dixon method using Leu-pNA as a substrate. The assay 
consists of reaction buffer, enzyme (0.1 µM) and Leu-pNA (30 µM, 80 µM, 200 µM, 





was varied in an appropriate range. Data were plotted as 1/rate vs. inhibitor 
concentration for each substrate concentration and a linear fit was calculated by non-
linear regression using SigmaPlot 13. All the experiments were carried out in triplicates 







Determination of inhibition constants (Ki) against PfA-M1: 
Compound 


















































Ki values were determined using Dixon plots of 1/rate versus inhibitor concentration for each 
substrate concentration. Substrate concentration was maintained lower than that of the Km of 
the enzyme. 
 
